- Home
- NRO vs PBYI Comparison
NRO vs PBYI Comparison
Compare NRO & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRO | PBYI |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.6M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NRO | PBYI |
|---|---|---|
| Price | $3.02 | $6.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 239.4K | ★ 378.0K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 11.41% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.28 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.51 | $2.58 |
| 52 Week High | $3.45 | $6.22 |
Technical Indicators
Market Signals| Indicator | NRO | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 54.86 | 68.34 |
| Support Level | $2.91 | $5.51 |
| Resistance Level | $3.06 | $5.73 |
| Average True Range (ATR) | 0.03 | 0.23 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 96.00 | 98.31 |
Price Performance
Historical ComparisonAbout NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.